Italian antitrust watchdogs have entered the Avastin-vs.-Lucentis fray. The Italian Competition Authority opened an investigation of Roche ($RHHBY) and Novartis ($NVS) on suspicion of a "cartel" designed to preference the vision-loss drug Lucentis over Avastin, the cancer drug sometimes used off-label in eye treatments.
A new small-molecule drug developed by cancer researchers has a remarkable effect in mice--it jump-starts a tumor-destroying system in the body, essentially driving cancer cells to suicide while protecting healthy tissue.
Two individuals have pleaded guilty in separate cases to importing and selling $7 million worth of unapproved oncology drugs to doctors in the U.S., shedding light on the perils of doctors buying foreign-made drugs and thinking they are getting equal quality at lower prices.
Could Avastin be on its way to another indication? On the heels of a broader approval for the drug in ovarian cancer in the EU, the U.S. National Institutes of Health has unveiled data showing Avastin helped patients with advanced cervical cancer live longer.
Some doctors, in an effort to save money, have been enticed to buy drugs through wholesalers who claim to get them from legitimate suppliers overseas. Sometimes the drugs are real meds made at foreign plants. But sometimes they have turned out to be counterfeits.
Chalk up another big win for Hal Barron and his R&D team extraordinaire at Genentech. The FDA today approved a new indication for Roche's ($RHHBY) cancer drug Avastin.
The Department of Homeland Security said it stepped up efforts to stop counterfeit products last year but ended up intercepting significantly fewer counterfeit pharmaceuticals than the year before.
While lifestyle drugs such as Viagra may still be the most counterfeited drugs around the world, international authorities are finding that some of those making fake drugs are turning more often to high-priced and life-saving cancer medications.
The FDA is warning healthcare providers that counterfeit drugs can slip into the U.S. when they stray from the approved supply chain to source products and has notified 350 U.S. doctors that they may have purchased unapproved and possibly counterfeit versions of Allergan's anti-wrinkle drug Botox.
Avastin has struck out at NICE again. The U.K. cost-effectiveness watchdog says it's not inclined to back the blockbuster Roche ($RHHBY) drug as a treatment for ovarian cancer. At about $4,000 per month, NICE said, Avastin simply doesn't deliver enough value for the money.